1. Scrip
  2. >>R&D

Aurobindo Expects To Be In Top Three For Immunology Biosimilar - Is It Xolair?

Pneumococcal Vaccine Filing In H2

 
• By Vibha Ravi

Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar. Scrip examines if it could it be a biosimilar to Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23

Clinical Research Image
Aurobindo Is Making Progress In Biosimilars' Development • Source: Shutterstock

Aurobindo Pharma Limited is gearing up to make its first immunology biosimilar filing in FY24/25, with regulatory approval likely to open the gateway to a $4bn opportunity for the drug in markets like Europe and US should it be among the first three companies to launch.

So far, it has filed applications for two oncology biosimilars in the European Union via its subsidiary CuraTeQ Biologics Private Ltd. The first was for a pegfilgrastim rival to Amgen, Inc

“We have advanced one of our very important immunology assets into Phase I clinical trial in Australia/New Zealand in Q4 of the last fiscal year [ended 31 March 2022], with the potential of it moving into a global Phase III trial by Q3 or Q4 of this year [FY23],” Satakarni Makkapati, CEO of Aurobindo's biosimilars, vaccines and peptides

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.